Brachystemma calycinum D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled TrialChondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science studyContribution of H3K4 methylation by SET-1A to interleukin-1-induced cyclooxygenase 2 and inducible nitric oxide synthase expression in human osteoarthritis chondrocytesEndothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production.The Novartis-ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to manThe protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Cartilage-specific deletion of ephrin-B2 in mice results in early developmental defects and an osteoarthritis-like phenotype during aging in vivo.A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life settingDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEOConcurrent validity of different functional and neuroproteomic pain assessment methods in the rat osteoarthritis monosodium iodoacetate (MIA) modelKinetic peak vertical force measurement in cats afflicted by coxarthritis: data management and acquisition protocols.First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort.Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes.Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort.Long-Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six-Year Followup Data From the Osteoarthritis Initiative.Osteoarthritis: a metabolic disease induced by local abnormal leptin activity?Human hip joint cartilage: MRI quantitative thickness and volume measurements discriminating acetabulum and femoral head.Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis.Evoked temporal summation in cats to highlight central sensitization related to osteoarthritis-associated chronic pain: a preliminary studyThe association between subchondral bone cysts and tibial cartilage volume and risk of joint replacement in people with knee osteoarthritis: a longitudinal study.High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes.Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging.Clinical validity of outcome pain measures in naturally occurring canine osteoarthritisPPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview.The role of cytokines in osteoarthritis pathophysiology.Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults.Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes.Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRIThe presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study.Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity.Does a placebo effect really occur in dogs afflicted by hip osteoarthritis as measured by force platform gait analysis?Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial.Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament modelCyclooxygenase-2 and prostaglandins in articular tissues.Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblastsThe shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein.Extracellular localization of galectin-3 has a deleterious role in joint tissuesKnee meniscal extrusion in a largely non-osteoarthritic cohort: association with greater loss of cartilage volume.
P50
Q21285007-546E75B6-A79C-4449-8D8B-F658945CC5C0Q22000858-9AF1184C-CABE-4300-B914-F30B5EAB703CQ24300761-19F2BC50-2B84-4709-9B82-B8F08A7A5A1CQ24804001-182B772A-50F7-4084-B320-803AAA838601Q24805915-8F1E25AB-88B5-4BAC-A1FB-C36B65BF914EQ24812406-E44BF7F1-8873-4450-850B-DC4C7CAD09F2Q27015782-A1B279DF-B44B-46B5-A4C6-901124AB2773Q27325791-574EACCA-F90E-4137-BCFB-9FE37FEB660DQ28073729-D8C39A71-E356-47D3-93DA-6E0ADB09CC7FQ28079515-AB756C27-DD79-42D6-B922-42D45BFB0812Q28829244-B4D272FB-8FA7-4EB2-9F45-9C436E74B708Q30589519-9CE5BE29-AB88-490C-82A1-5974418D829DQ30714596-F6785C7E-71D9-4DB3-8FF9-DCAE1605A234Q30931885-AEFBB80F-0A59-42BB-AB15-AFA7B091CF1FQ30975609-FF0D7B41-6525-42A1-A024-9601DAD32635Q31046250-C0563F39-2C78-45F4-A98C-B988AA95D8ADQ33212755-C874E025-39F7-44AD-AEBA-035BB61F179DQ33397893-9818DCAA-64E1-4085-BC27-BBDC50445A9FQ33558810-8B18FB26-0B59-4435-A005-B634372427BDQ33654756-1DC7B3F1-68CF-4578-B942-4D8126941508Q33923385-05C4DAC3-3851-46D5-96C9-0AEACE41F2F6Q34153150-96C9475A-BB62-478D-8411-14C34B56EF90Q34346229-9C8B0569-AED6-42F4-8EBE-DB7AC322D252Q34410470-92C8559F-C83B-4C95-9CBB-70A03C2D2F1CQ34515090-DBA95AEF-8348-4851-A2A7-84107992F423Q34524517-C5D5EC85-9652-4B4A-BEFD-137F9221A9D4Q34614059-B66B25AF-E970-4941-B38B-E6DA41D4B477Q34896028-2BEA5F57-12F9-4B7B-8F19-BAD3800D1391Q34896866-6D679443-28A4-4EF5-9208-B7E1EA0C6B9DQ34906145-A4427BBC-DA35-4B13-987B-F8B63DC42F30Q34967738-A1878842-4E1A-47A8-B71B-B45C20EF3D32Q35030853-0DAEE6E9-7058-4627-A7B5-7DD84668911EQ35073848-72DF3423-2141-4365-859B-AF1E2765C6C1Q35531158-0F7BDEFF-6688-4389-ABB0-CCF41D0C0583Q35557938-1F345443-7F3D-4F1D-B784-50EF691FCE84Q35606373-7EC90CEE-A419-4B2B-B730-1F015583EA31Q35630082-CD7F8E7A-9BB5-4326-81C1-7DB71E00E6F1Q35630102-B595A7C7-A2F4-4D5F-A08E-B12F6D0CDF44Q35769105-52725DE4-B881-4C94-8930-37F39C0871D4Q35868964-568FB4DA-1295-4B2F-96CD-2B772A5C155F
P50
description
Canadees onderzoeker (1952-)
@nl
Canadian researcher
@en
investigador canadiense
@es
kanadischer Mediziner
@de
taighdeoir Ceanadach
@ga
name
Jean-Pierre Pelletier
@af
Jean-Pierre Pelletier
@an
Jean-Pierre Pelletier
@ast
Jean-Pierre Pelletier
@bar
Jean-Pierre Pelletier
@bm
Jean-Pierre Pelletier
@br
Jean-Pierre Pelletier
@ca
Jean-Pierre Pelletier
@co
Jean-Pierre Pelletier
@cs
Jean-Pierre Pelletier
@cy
type
label
Jean-Pierre Pelletier
@af
Jean-Pierre Pelletier
@an
Jean-Pierre Pelletier
@ast
Jean-Pierre Pelletier
@bar
Jean-Pierre Pelletier
@bm
Jean-Pierre Pelletier
@br
Jean-Pierre Pelletier
@ca
Jean-Pierre Pelletier
@co
Jean-Pierre Pelletier
@cs
Jean-Pierre Pelletier
@cy
prefLabel
Jean-Pierre Pelletier
@af
Jean-Pierre Pelletier
@an
Jean-Pierre Pelletier
@ast
Jean-Pierre Pelletier
@bar
Jean-Pierre Pelletier
@bm
Jean-Pierre Pelletier
@br
Jean-Pierre Pelletier
@ca
Jean-Pierre Pelletier
@co
Jean-Pierre Pelletier
@cs
Jean-Pierre Pelletier
@cy
P1006
P214
P244
P1006
P101
P106
P21
P213
0000 0000 3302 1490
P214
P244
n2001033815
P27
P31
P4450
jean-pierre-pelletier
P569
1952-01-01T00:00:00Z
P734
P735
P7859
lccn-n84803313